News about Global Pharma

Emcure Reports Robust Q1 FY27 Results, PAT Surges 36 Percent

Emcure Pharmaceuticals reported a strong Q1 FY27 with 22.8 percent revenue growth, 36.2 percent higher profit, improved margins, robust performance across key therapies, and over 15 product approvals in global markets.

Global Pharma | 07/08/2026 | By News Bureau

Karyopharm to Seek US FDA Accelerated Approval for Selinexor-Ruxolitinib Combination in Myelofibrosis

Karyopharm Therapeutics plans to file an sNDA with the US FDA seeking accelerated approval for selinexor in combination with ruxolitinib for myelofibrosis. Supported by positive Phase 3 SENTRY trial results, the combination has the potential to become the first approved frontline combination therapy for the rare blood cancer.

Global Pharma | 03/08/2026 | By News Bureau

Kaigene Licenses Autoimmune Drug KG006 to Taisho Pharma in Japan

Taisho Pharmaceutical secures exclusive rights to clinically develop, register, and commercialise Kaigene's next-generation FcRn inhibitor, KG006, in Japan.

Global Pharma | 01/08/2026 | By News Bureau

Johnson & Johnson's RYBREVANT FASPRO Gets US FDA Priority Review for Advanced Head and Neck Cancer

Johnson & Johnson's RYBREVANT FASPRO has received US Food and Drug Administration (FDA) Priority Review (PR) as a potential first-in-class subcutaneous treatment for advanced head and neck cancer.

Global Pharma | 01/08/2026 | By News Bureau |  104

Johnson & Johnson Partners with Sail Biomedicines to Advance In Vivo CAR-T Therapies

Johnson & Johnson has entered into a collaboration with Sail Biomedicines to develop in vivo CAR-T therapies for immune-mediated diseases that includes a USD 465 million equity investment, milestone-based payments and an exclusive option to acquire Sail Biomedicines for USD 2.58 billion.

Global Pharma | 31/07/2026 | By News Bureau

American Regent Issues Voluntary Nationwide Recall of One Lot of Papaverine Hydrochloride Injection

American Regent has recalled one lot of Papaverine Hydrochloride Injection nationwide due to visible glass and paraformaldehyde particulate matter.

Global Pharma | 27/07/2026 | By News Bureau

Sanofi to not Submit Amlitelimab in Atopic Dermatitis for Global Regulatory Reviews

Sanofi will not seek global regulatory approval for amlitelimab in Atopic Dermatitis (AD) after efficacy and safety data did not support further development.

Global Pharma | 27/07/2026 | By News Bureau

US FDA Approves TYLENOL with Naproxen for OTC Use

The US Food and Drug Administration (FDA) has approved TYLENOL with Naproxen, the first OTC fixed-dose acetaminophen and naproxen combination offering up to 12 hours of pain relief.

Global Pharma | 25/07/2026 | By News Bureau |  144

Nona Biosciences Partners with Medical University of Vienna on Antibody Research

Nona Biosciences has partnered with the Medical University of Vienna to advance fully human antibody development for infectious diseases using its H2L2 Harbour Mice platform.

Global Pharma | 23/07/2026 | By News Bureau

Takeda and Indonesia Partner to Expand Access to Plasma-Derived Medicines

Takeda and Indonesia have partnered to strengthen healthcare resilience, expand access to plasma-derived medicines, and establish a national plasma donation ecosystem with an initial USD 30 million investment.

Global Pharma | 13/07/2026 | By News Bureau